Safety Information

The safety of CIMZIA in Crohn’s disease has been assessed in randomized, placebo-controlled, double-blind, and open-label extension studies lasting from 26 weeks to 4 years. In those studies^1,2:

• 8% of patients discontinued therapy due to adverse events in clinical trials (vs 7% for placebo)
• There was a low incidence of injection site burning and stinging

Learn more about the safety profile of CIMZIA:

• Dosing Tolerability
• Adverse Events
• Special Precautions
• Medication Guide and Prescribing Information

References:

1. CIMZIA [prescribing information]. Smyrna, GA: UCB, Inc.; 2009.
2. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007;357:239-250.